R3 Weight loss: what is R3 (retatrutide)?
The "R3" everyone's talking about for weight loss is retatrutide. Retatrutide (LY3437943) is the first triple GLP-1/GIP/glucagon agonist to enter a phase 3 clinical trial. With a reduction in body weight of up to 24% in phase 2 studies, it surpasses in efficacy all molecules known to date in obesity research.
What is R3 for weight loss?
R3 is the nickname for retatrutide (code LY3437943), a molecule developed by Eli Lilly. "R3" refers to its three receptors: GLP-1, GIP, and glucagon. It is also known as "Reta," "the R," “ GLP-3 ” or even “ratatouille” on TikTok and Instagram, where people talk about “R3 for slimming” or “R3 weight loss”.
- This is not an authorized medication Retatrutide is still in phase 3 clinical trials. It does not have marketing authorization in France or Europe, and it is not sold in pharmacies.
- It is not available in tablet form. In clinical trials, it is administered by weekly injection. What is circulating in Europe is a lyophilized powder in a vial, sold as a research peptide.
- Why is it being talked about so much? : this is the molecule that has achieved the highest average weight loss ever published for this type of treatment, ahead of semaglutide and tirzepatide (detailed figures below).
R3 peptide at MyPeptide: R3 peptide 10 mg (lyophilized retatrutide powder, intended exclusively for scientific research) is €59.90, with verifiable Janoshik analysis reports. All formats, from 10 to 60 mg, are available on our retatrutide purchase page.
What is Retatrutide?
Retatrutide (INN name, development code LY3437943) is a molecule developed by Eli Lilly that belongs to the new class of multi-receptor incretin agonists. Unlike Semaglutide (a mono-GLP-1 agonist) or Tirzepatide (a dual GLP-1/GIP agonist), Retatrutide simultaneously activates three distinct receptors:
- GLP-1 Receptor (Glucagon-Like Peptide-1) — regulation of appetite, slowing of gastric emptying, stimulation of insulin
- GIP Receptor (Glucose-Dependent Insulinotropic Polypeptide) — potentiation of the insulinotropic effect, reduction of postprandial glucagon levels
- Glucagon receptor — increased energy expenditure, increased hepatic lipolysis, reduced de novo lipogenesis
It is this simultaneous triple action that fundamentally distinguishes Retatrutide and explains its superior effectiveness on fat mass compared to previous generations of GLP-1 peptides.
Retatrutide is a 39-amino-acid peptide conjugated to a C18 fatty acid chain via a spacer, giving it a prolonged half-life of approximately 6 days (allowing for weekly administration in a clinical protocol). Its molecular mass is approximately 4,720 Da.
Mechanism of action: how Retatrutide affects weight
Action on the GLP-1 receptor — appetite control
Activation of the GLP-1 receptor (GLP-1R) in the hypothalamus and the nucleus of the solitary tract induces a reduction in food intake via several pathways:
- Reduction of circulating ghrelin (the hunger hormone)
- Increased satiety signals (peptide YY, CCK)
- Slowing of gastric emptying (increased feeling of prolonged satiety)
- Activation of POMC/CART neurons and inhibition of NPY/AgRP neurons in the hypothalamus
Action on the GIP receptor — metabolic potentiation
GIP (formerly known as "gastric inhibitory hormone") plays a complex role in lipid and glucose metabolism. Activation of the GIP receptor (GIPR) by Retatrutide:
- Potentiates the glucose-dependent insulinotropic effect (insulin sensitizer)
- Reduces insulin resistance in adipose tissue
- Modulates lipogenesis in adipocytes
- Improves bone metabolism (effect observed in research)
Action on the glucagon receptor — the differentiating novelty
This is where Retatrutide differs radically from Tirzepatide. Activation of the glucagon receptor (GCGR):
- Increases basal energy expenditure (hepatic thermogenesis and adipose tissue)
- Stimulates hepatic lipolysis — mobilization of fats stored in the liver (NAFLD/NASH)
- Reduces de novo lipogenesis in the liver
- Promotes mild ketogenesis, preferential use of fatty acids as an energy substrate
This glucagon component explains why Retatrutide shows a particularly marked reduction in liver fat in studies, in addition to overall fat mass loss.
Results of clinical trials
Phase 2 — Results published (NEJM 2023)
The phase 2 multicenter, randomized, double-blind, placebo-controlled study, published in the New England Journal of Medicine in 2023, included 338 adults with obesity (BMI ≥ 30) over a period of 48 weeks.
| Dose tested | Average weight loss at 48 weeks | % of participants ≥ 15% loss | % of participants ≥ 20% loss |
|---|---|---|---|
| Placebo | -2,1% | 1% | 0% |
| Retatrutide 1 mg | -8,7% | 18% | 6% |
| Retatrutide 4 mg | -17,1% | 53% | 32% |
| Retatrutide 8 mg | -22,8% | 73% | 50% |
| Retatrutide 12 mg | -24.2% | 83% | 62% |
For comparison, Semaglutide 2.4 mg (Wegovy) achieved -15% in 68 weeks in the STEP-1 study, and Tirzepatide 15 mg (Mounjaro) achieved -22.5% in 72 weeks in the SURMOUNT-1 study. Retatrutide 12 mg achieved -24.2% in only 48 weeks.
Side effects observed in phase 2
The adverse effect profile is consistent with the class of GLP-1 agonists:
- Nausea: 40-60% (dose-dependent, usually transient during the titration phase)
- Vomiting: 15-30%
- Diarrhea : 20-35%
- Constipation : 15-25%
- Mild tachycardia: observed with high doses (glucagon component)
- Discontinuation due to adverse effects: ~7% of participants (12 mg dose)
Phase 3 — ongoing (TRIUMPH-1, TRIUMPH-2, TRIUMPH-3)
Eli Lilly launched the TRIUMPH program in 2024 for phase 3 studies of Retatrutide in obesity, with three major trials:
- TRIUMPH-1: obesity without comorbidity (n ≈ 2000, 72 weeks)
- TRIUMPH-2: obesity + type 2 diabetes (n ≈ 1500)
- TRIUMPH-3: obesity + high cardiovascular risk (MACE)
Retatrutide vs Semaglutide vs Tirzepatide — Comparative Table
| Criteria | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Mechanism | GLP-1 monoagonist | GLP-1 + GIP | GLP-1 + GIP + GCG |
| Maximum weight loss (trials) | ~15% (68 weeks) | ~22.5% (72 weeks) | ~24.2% (48 weeks) |
| Liver fat reduction | Moderate | High | Very high |
| Basal energy expenditure | Slightly modified | Slightly modified | Augmented (GCG) |
| Stage of development | Marketed | Marketed | Phase 3 |
| Research availability | Available | Available | Available |
| Half-life | ~7 days | ~5 days | ~6 days |
The role of the glucagon receptor in fat loss
The glucagonergic component is the key element that differentiates Retatrutide and justifies the particular scientific interest in this molecule in research protocols on body composition.
Historically, researchers feared that activating the glucagon receptor would induce problematic hyperglycemia. Eli Lilly resolved this tension by balancing the relative activities: strong GLP-1/GIP activation sufficiently stimulates insulin secretion to counteract the hyperglycemic effect of glucagon, while preserving the metabolic benefits (thermogenesis, lipolysis) of GCGR activation.
Phase 2 data show that Retatrutide preferentially reduces visceral fat mass (the most metabolically harmful adipose tissue) and liver adipose tissue, while preserving lean mass more effectively compared to Semaglutide alone. Follow-up studies with DEXA are ongoing in the TRIUMPH program.
Retatrutide and NASH/NAFLD: an additional benefit
Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are major comorbidities of obesity. Phase 2 data show an 82% reduction in liver fat content with Retatrutide 12 mg versus a 0.3% increase with placebo after 24 weeks, as measured by MRI-PDFF (Sanyal et al., Nature Medicine 2024).
Eli Lilly is also conducting specific trials of Retatrutide in NASH, where the glucagon component (direct hepatic lipolysis) represents a specific mechanistic advantage.
Applications in preclinical research
In a laboratory research setting, Retatrutide is being studied for:
- Experimental modeling of obesity and its metabolic comorbidities
- The study of incretin signaling pathways (GLP-1R, GIPR, GCGR) and their synergistic interactions
- Research on the gut microbiota and its interaction with GLP-1 agonists
- Investigating the neuroendocrine effects on food reward circuits
- Models of hepatic steatosis and metabolic inflammation
Order Retatrutide for your research
MyPeptide offers research-grade Retatrutide, HPLC certified 99%+, with a Janoshik COA available before purchase. Discreet shipping within 2 to 5 business days from the European Union.
Frequently Asked Questions about the R3
Is R3 a medicine?
No. R3 (retatrutide) is not yet an authorized medicine: Eli Lilly is conducting phase 3 trials (TRIUMPH program) and no application for authorization has been submitted in Europe to date. Therefore, R3 is not available in pharmacies, nor can it be prescribed. The country-by-country status is detailed on our page about the legal status of retatrutide in Europe, and the questions about pharmacies, prescriptions, and tablets on the page about whether R3 is a medicine.
How much weight does the R3 lose in testing?
In the phase 2 trial published in the New England Journal of Medicine (2023), the average weight loss reached 24.2% at 48 weeks at a weekly dose of 12 mg, compared to 2.1% with placebo. These are averages from medically supervised clinical trials, not a promise of individual results.
Is R3 available in tablet form?
No. Retatrutide is not available in tablet or capsule form; trials use it as a weekly injection. A product sold as "R3 tablets" is not retatrutide.
What is the difference between R3, semaglutide and tirzepatide?
Semaglutide activates one receptor (GLP-1), tirzepatide two (GLP-1 and GIP), and R3 three (GLP-1, GIP, and glucagon). The glucagon receptor increases energy expenditure, which explains the greater weight loss observed in the trials.
Where can I find R3 and at what price?
R3 is only available as a research peptide from online vendors. Prices range from €5 to €12.50 per mg depending on the vendor: see our R3 price comparison in France and our criteria for choosing a retatrutide supplier. At MyPeptide, R3 peptide 10 mg is €59.90, with verifiable Janoshik reports.
Key points to remember
- Retatrutide is a triple GLP-1/GIP/glucagon agonist — the first molecule of its class in phase 3
- Average weight loss of -24.2% over 48 weeks at a dose of 12 mg (phase 2)
- The glucagon component increases basal energy expenditure and hepatic lipolysis — a mechanism absent in Semaglutide and Tirzepatide
- Tolerability profile similar to GLP-1 class (nausea mainly during the titration phase)
- Of particular interest for NAFLD/NASH research due to the combined hepatoprotective effect
- Phase 3 (TRIUMPH program) underway since 2024
Scientific sources: Jastreboff et al., NEJM 2023 — Retatrutide Phase 2 · NCT04881760 — Phase 2 Clinical Trial
📦 Buy Retatrutide in Europe
Available at MyPeptide.eu · Delivery France, Germany, Italy, Spain · COA HPLC 99%+
Scientific sources
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial — Jastreboff AM et al. (2023)
- Retatrutide Shows Multiple Metabolic Benefits in Diet-Induced Obese MASH Mouse and Hamster Models — Briand F et al. (2026)
- The Triple-Agonist Revolution: Retatrutide and the Paradigm Shift in Multi-Hormonal Pharmacotherapy for Obesity and Cardiometabolic Comorbidities — Ganamurali N et al. (2026)
- Retatrutide Phase 3 — Weight Loss Maintenance (TRIUMPH-6) — ClinicalTrials.gov (2025)
To compare with other GLP-1 molecules, see our Retatrutide vs Tirzepatide vs Semaglutide comparison.

